The $1.2 billion Dermavant acquisition appears strategically acceptable but carries significant risks due to market ...

CWA Asset Management Group LLC acquired a new position in Organon & Co. (NYSE:OGN – Free Report) in the third quarter, ...

Organon (OGN) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of ...

On Tuesday, Organon & Co (OGN) stock saw a decline, ending the day at $16.46 which represents a decrease of $-0.46 or -2.72% from the prior close of $16.92. The stock opened at $16.74 and touched a ...

Investors in Organon & Co. OGN need to pay close attention to the stock based on moves in the options market lately. That is because the Dec. 20, 2024 $2.50 Call had some of the highest implied ...

For the quarter ended September 2024, Organon (OGN) reported revenue of $1.58 billion, up 4.2% over the same period last year. EPS came in at $0.87, compared to $0.87 in the year-ago quarter. The ...

Organon & Co. ( (OGN) ) has released its Q3 earnings. Here is a breakdown of the information Organon & Co. presented to its ...

Despite announcing strong earnings, Organon & Co.'s ( NYSE:OGN ) stock was sluggish. We did some digging and found ...

Analyst Terence Flynn of Morgan Stanley maintained a Hold rating on Organon (OGN – Research Report), reducing the price target to $17.00.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...